Chris’ practice is in the pharmaceutical area of life sciences. He handles cases relating to new chemical entities, formulations, polymorphs and dosage regimens for innovator clients such as Gilead and Novartis, and has successfully defended a number of commercially important patents protecting blockbuster products. Chris is experienced as lead counsel in multiparty EPO opposition and appeal proceedings (both in attack and defence), and in providing support during parallel national litigation. He also advises on complementary aspects of pharmaceutical IP, including SPCs and regulatory law. He has been commended for his work by Managing IP in IP Stars.
Prior to joining Carpmaels & Ransford, Chris graduated with a first-class MChem degree from the University of Durham. He was awarded the BP prize for his Master’s work on trimeric cyclic assemblies of calixarene-tethered bismerocyanine dyes. As part of his degree, Chris spent a year on an Erasmus exchange in Prof. Dr. Frank Würthner’s laboratory at the University of Würzburg, Germany.
- MChem (Hons) (University of Durham)
- Chartered Patent Attorney
- European Patent Attorney
- Truvada® – Gilead v Teva & Generics (Formulations)
- Biktarvy® (and other tenofovir alafenamide-containing products) – Gilead v four opponents (New chemical entities)
- Genvoya® (and other cobicistat-containing products) – Gilead v multiple opponents (New chemical entities & combinations)
- Tasigna® – Novartis v multiple opponents (Formulations & Polymorphs, enantiomers and salt forms)
- Aclasta® – Novartis v multiple opponents (Dosage regimens)